Nanomedicine and targeted drug delivery
5 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Barcelona bioengineering institute specializing in mechanobiology, organ-on-chip tissue models, nanomedicine, and bioprinting for health applications.
“NANOSTORM, THERACAT, CheSSTaG, MICROCLEANERS, and LABPATCH all address nanoparticle-based therapies, bio-orthogonal catalysis, or chemotactic targeting of tumors.”
PrimaryES48 projects - HUMANITAS MIRASOLE SPA
Italian private research hospital strong in ALS, cardiovascular repair, immunology, and nanomedicine, now expanding into multi-omics precision medicine.
“NANOTAM developed nanomedicines for cancer immunomodulation; MONONANOCHEM engineered monocytes loaded with nano-chemotherapeutics; miRCaP formulated nanoparticles for cardiac treatment.”
IT20 projects - BYONDIS BV
Dutch biopharmaceutical SME specializing in continuous bioprocessing, bioreactor control, and downstream manufacturing of drug proteins and biologics.
“NANOMED (2016-2019) contributed to an integrative approach to nanomedicine through an MSCA-ITN training network.”
SMENL3 projects - APTUIT (VERONA) SRL
Italian contract research organization providing preclinical pharmaceutical development, drug formulation, and industrial training for EU anti-infective and nanomedicine projects.
“FOLSMART (largest grant at EUR 653K) involved folate-targeted nanodevices for rheumatoid arthritis treatment, indicating capability in nanoformulation.”
IT3 projects - BLUEPHARMA - INDUSTRIA FARMACEUTICASA
Portuguese pharmaceutical SME with rheumatoid arthritis focus, contributing industrial drug formulation and manufacturing expertise to EU clinical and nanomedicine consortia.
“FOLSMART explored folate-targeted nanodevices directed at activated macrophages, placing Bluepharma at the interface of nanoformulation and immune-cell-targeted therapeutics.”
SMEPT2 projects